AtriCure, Inc.

ATRC • Medical - Instruments & Supplies

$51.52

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$2.53B

Crecimiento

33.3%

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Crecimiento positivo de ingresos · 16.5%Flujo de caja libre positivo · 1.01Nivel de deuda manejable · 0.18Liquidez saludable · 3.96Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$51.52

Change0.00%

Shares Out49.09M

Market Cap$2.53B

Enterprise Value$2.42B

52W Range25.36 - 43.18

Beta1.25

P/E239.70

P/S4.44

P/B4.90

P/FCF47.62

EV/Sales4.25

Price$51.52

Change0.00%

Shares Out49.09M

Market Cap$2.53B

Enterprise Value$2.42B

52W Range25.36 - 43.18

Beta1.25

P/E239.70

P/S4.44

P/B4.90

P/FCF47.62

EV/Sales4.25

EV/EBITDA93.38

EV/FCF45.61

Earnings Yield0.42%

FCF Yield2.10%

Dividend Yield0.00%

Gross Margin74.41%

Oper. Margin-0.64%

Profit Margin-2.14%

Debt/Eq0.18

Current Ratio3.96

Quick Ratio2.99

Revenue 5Y33.29%

Target$56.00

Target Upside8.70%

Target Median$55.00

Target Range50.00 - 64.00

Volume1.04M

Avg Volume930.62K

EPS Surprise0.07

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

49/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 16.5%Flujo de caja libre positivo · 1.01Nivel de deuda manejable · 0.18Liquidez saludable · 3.96Rentabilidad débil

Analyst view

Analyst sentiment and price target

ATRC

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

97/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-29

Bajo

$44.00

Promedio

$50.25

Mediana

$51.00

Alto

$55.00

Resumen de la compañía

IPO: 8/5/2005

Industria: Medical - Instruments & Supplies

P/B i: 4.90

Deuda / Patrimonio i: 0.18

Margen operativo: -0.64%

Margen neto: -2.14%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.18

Ratio corriente: 3.96

Ratio rápido: 2.99

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Privitera Salvatore

Transacción: 06/30/2026

COMPRA

Cambio

+636

Precio

$23.78

Presentación

07/02/2026

Tipo

COMPRA

Seith Douglas J

Transacción: 06/30/2026

COMPRA

Cambio

+527

Precio

$23.78

Presentación

07/02/2026

Tipo

COMPRA

Dahlquist Karl S.

Transacción: 06/30/2026

COMPRA

Cambio

+636

Precio

$23.78

Presentación

07/02/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Privitera Salvatore	COMPRA	+636	$23.78	06/30/2026	07/02/2026
Seith Douglas J	COMPRA	+527	$23.78	06/30/2026	07/02/2026
Dahlquist Karl S.	COMPRA	+636	$23.78	06/30/2026	07/02/2026
Doraiswamy Vinayak	COMPRA	+636	$23.78	06/30/2026	07/02/2026
CARREL MICHAEL H	COMPRA	+636	$23.78	06/30/2026	07/02/2026
Prange Karen	VENTA	-3,000	$28.65	05/20/2026	05/22/2026
WHITE ROBERT S.	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
WEHRWEIN SVEN	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
GROVES REGINA E	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
JOHNSON B KRISTINE	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
Nachman Shlomo	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
Yuen Maggie	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
Telman Deborah H	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
Prange Karen	COMPRA	+6,144	Not reported	05/18/2026	05/20/2026
Doraiswamy Vinayak	VENTA	-5,000	$28.13	05/15/2026	05/18/2026
Doraiswamy Vinayak	VENTA	-5,000	$29.83	03/12/2026	03/16/2026
WHITE ROBERT S.	VENTA	-10,000	$14.99	03/10/2026	03/12/2026
WHITE ROBERT S.	COMPRA	+10,000	$14.99	03/10/2026	03/12/2026
CARREL MICHAEL H	VENTA	-1,000	Not reported	03/06/2026	03/09/2026
Dahlquist Karl S.	VENTA	-15,687	$31.26	03/01/2026	03/03/2026

Sobre la compañía

AtriCure, Inc.

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

Fuente - Link

Competidores

AZTA BLFS IMCR KMTS LMAT NVCR QDEL SEM TXG XERS

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Investment Research

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.

Business Wire

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

Seeking Alpha

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

MarketBeat

A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95

On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s

GuruFocus

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-05	-0.07	0.0022	0.0722
2026-02-17	-0.04003	0.06	0.10003
2025-10-29	-0.11	-0.01	0.1
2025-07-29	-0.15	-0.02	0.13
2025-04-29	-0.25	-0.14	0.11
2025-02-12	-0.23	-0.08	0.15
2024-10-29	-0.2	-0.17	0.03
2024-07-30	-0.15	-0.17	-0.02
2024-05-01	-0.21	-0.25	-0.04
2024-02-15	-0.22	-0.21	0.01
2023-11-01	-0.3	-0.2	0.1
2023-07-25	-0.27	-0.12	0.15